15-hydroxyeicosatrienoic acid profile

## 15-Hydroxyeicosatrienoic Acid (15-HETE): A Powerful Lipid Mediator

15-HETE is a **lipid mediator** produced by the enzymatic oxidation of arachidonic acid, a fatty acid found in cell membranes. It belongs to the family of **hydroxy fatty acids**, specifically the **eicosanoids**, which play important roles in various physiological processes.

**Why is 15-HETE important for research?**

15-HETE is involved in a wide range of biological functions, including:

* **Inflammation:** 15-HETE is a potent pro-inflammatory mediator. It can promote leukocyte adhesion, activation, and chemotaxis, contributing to inflammation and immune responses.
* **Cell Proliferation and Differentiation:** 15-HETE can influence cell growth and differentiation in various tissues, including the skin, liver, and vascular system.
* **Vascular Function:** 15-HETE contributes to vascular tone regulation by affecting smooth muscle cell contraction and relaxation. It also impacts vascular permeability and blood flow.
* **Cardiovascular Disease:** 15-HETE has been linked to the development of cardiovascular disease. It can contribute to atherosclerosis, platelet aggregation, and thrombosis.
* **Cancer:** 15-HETE has been implicated in cancer development and progression. It can promote tumor growth, angiogenesis, and metastasis.

**Research Focus:**

* **Therapeutic Targets:** The diverse roles of 15-HETE make it a potential therapeutic target for various diseases. Researchers are investigating inhibitors and agonists of 15-HETE biosynthesis and signaling pathways.
* **Biomarker Potential:** 15-HETE levels can be used as a biomarker for inflammatory conditions, cardiovascular disease, and cancer. Further research is needed to determine its clinical utility.
* **Mechanism of Action:** Scientists are actively studying the detailed mechanisms by which 15-HETE exerts its biological effects. This includes identifying its receptors, downstream signaling pathways, and interactions with other lipid mediators.
* **Therapeutic Potential:** 15-HETE has shown potential in treating certain conditions. For example, it has been investigated for its anti-inflammatory and anti-cancer effects.

**Conclusion:**

15-HETE is a crucial lipid mediator with diverse and complex roles in the body. Its involvement in various physiological and pathological processes makes it a significant target for research in multiple fields. Further investigations are needed to fully understand its functions and develop therapeutic strategies utilizing its potential.

15-hydroxyeicosatrienoic acid: the 15-lipoxygenase product of dihomogammalinolenic acid; inhibits the biosynthesis of the proinflammatory eicosanoids leukotriene B4 (LTB4) and 12-hydroxyeicosatetraenoic acid [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	133910
MeSH ID	M0250551

Synonym
eicosatrienoic acid, 15-hydroxy-
82451-61-4
15-hydroxyeicosatrienoic acid
15-hydroxyicosa-2,4,6-trienoic acid
DTXSID00904332

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	3 (23.08)	18.2507
2000's	6 (46.15)	29.6817
2010's	3 (23.08)	24.3611
2020's	1 (7.69)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (7.69%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	12 (92.31%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
14,15-epoxy-5,8,11-eicosatrienoic acid 14,15-epoxy-5,8,11-eicosatrienoic acid: RN given refers to cpd without isomeric designation	2	1	long-chain fatty acid
15-hydroxy-5,8,11,13,17-eicosapentaenoic acid 15-hydroxy-5,8,11,13,17-eicosapentaenoic acid: structure given in first source; RN given refers to parent cpd	3.87	2
aspirin Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.	3.85	3	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	2.03	1	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
sorafenib [no description available]	2.25	1	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
arachidonic acid icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.	2.42	2	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite
eicosapentaenoic acid icosapentaenoic acid : Any straight-chain, C20 polyunsaturated fatty acid having five C=C double bonds.. all-cis-5,8,11,14,17-icosapentaenoic acid : An icosapentaenoic acid having five cis-double bonds at positions 5, 8, 11, 14 and 17.	4.2	3	icosapentaenoic acid; omega-3 fatty acid	anticholesteremic drug; antidepressant; antineoplastic agent; Daphnia galeata metabolite; fungal metabolite; micronutrient; mouse metabolite; nutraceutical
caffeic acid trans-caffeic acid : The trans-isomer of caffeic acid.	2.04	1	caffeic acid	geroprotector; mouse metabolite
nadp [no description available]	2	1
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	2.44	2	prostaglandins E	human metabolite; mouse metabolite; oxytocic
linoleic acid Linoleic Acid: A doubly unsaturated fatty acid, occurring widely in plant glycosides. It is an essential fatty acid in mammalian nutrition and is used in the biosynthesis of prostaglandins and cell membranes. (From Stedman, 26th ed). linoleic acid : An octadecadienoic acid in which the two double bonds are at positions 9 and 12 and have Z (cis) stereochemistry.	2.03	1	octadecadienoic acid; omega-6 fatty acid	algal metabolite; Daphnia galeata metabolite; plant metabolite
8,11,14-eicosatrienoic acid 8,11,14-Eicosatrienoic Acid: A 20-carbon-chain fatty acid, unsaturated at positions 8, 11, and 14. It differs from arachidonic acid, 5,8,11,14-eicosatetraenoic acid, only at position 5.. all-cis-icosa-8,11,14-trienoic acid : An icosatrienoic acid having three cis double bonds at positions 8, 11 and 14.	2.4	2	fatty acid 20:3; long-chain fatty acid	fungal metabolite; human metabolite; nutraceutical
misoprostol Misoprostol: A synthetic analog of natural prostaglandin E1. It produces a dose-related inhibition of gastric acid and pepsin secretion, and enhances mucosal resistance to injury. It is an effective anti-ulcer agent and also has oxytocic properties.. misoprostol : A diastereoisomeric mixture composed of approximately equal amounts of a double racemate of four of the sixteen possible diastereoisomers of methyl (13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate that is racemic prostaglandin E1 which is lacking the hydroxy group at position 15, but which has an additional hydroxy group at position 16. It is a synthetic prostaglandin E1 analogue, used in the treatment of gastric and duodenal ulcers. A weak abortifacient, it is also used for cervical ripening prior to surgical termination of pregnancy. The (11R,16S)-diastereoisomer is the pharmacologically active form.	2.04	1
11,12-dihydroxyeicosatrienoic acid (5Z,8Z,14Z)-11,12-dihydroxyicosatrienoic acid : A DHET obtained by formal dihydroxylation across the 11,12-double bond of arachidonic acid.	2	1	DHET	mouse metabolite
14,15-dihydroxyeicosatrienoic acid (5Z,8Z,11Z)-14,15-dihydroxyicosatrienoic acid : A DHET obtained by formal dihydroxylation across the 14,15-double bond of arachidonic acid.	2	1	DHET; diol; secondary allylic alcohol	mouse metabolite
sulprostone sulprostone: structure	2.04	1	prostanoid
12-hydroxy-5,8,10,14-eicosatetraenoic acid 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid: A lipoxygenase metabolite of ARACHIDONIC ACID. It is a highly selective ligand used to label mu-opioid receptors in both membranes and tissue sections. The 12-S-HETE analog has been reported to augment tumor cell metastatic potential through activation of protein kinase C. (J Pharmacol Exp Ther 1995; 274(3):1545-51; J Natl Cancer Inst 1994; 86(15):1145-51)	1.99	1
12-hydroxy-5,8,10,14,17-eicospentaenoic acid 12-hydroxy-5,8,10,14,17-eicospentaenoic acid: RN given refers to cpd without isomeric designation	2.25	1
phosphatidylcholines Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.	1.98	1	1,2-diacyl-sn-glycero-3-phosphocholine
11,12-epoxy-5,8,14-eicosatrienoic acid 11,12-epoxy-5,8,14-eicosatrienoic acid: RN given refers to cpd without isomeric designation. (11S,12R)-EET : An 11,12-EET in which the epoxy moiety has 11S,12R-configuration.. 11,12-EET : An EET obtained by formal epoxidation of the 11,12-double bond of arachidonic acid.	2	1	11,12-EET	human xenobiotic metabolite

Condition	Relationship Strength	Studies
Benign Neoplasms, Brain [description not available]	2.25	1
Glial Cell Tumors [description not available]	2.25	1
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	2.25	1
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	2.25	1
Acne [description not available]	4.95	4
Acne Vulgaris A chronic disorder of the pilosebaceous apparatus associated with an increase in sebum secretion. It is characterized by open comedones (blackheads), closed comedones (whiteheads), and pustular nodules. The cause is unknown, but heredity and age are predisposing factors.	4.95	4
Osteoarthritis of Knee [description not available]	2.1	1
Osteoarthritis, Knee Noninflammatory degenerative disease of the knee joint consisting of three large categories: conditions that block normal synchronous movement, conditions that produce abnormal pathways of motion, and conditions that cause stress concentration resulting in changes to articular cartilage. (Crenshaw, Campbell's Operative Orthopaedics, 8th ed, p2019)	2.1	1
Genetic Predisposition [description not available]	2.11	1
Aspirin Induced Asthma [description not available]	2.11	1
Eosinophilia, Tropical [description not available]	2.11	1
Innate Inflammatory Response [description not available]	2.46	2
Eosinophilia Abnormal increase of EOSINOPHILS in the blood, tissues or organs.	2.11	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.46	2
Nasal Polyps Focal accumulations of EDEMA fluid in the NASAL MUCOSA accompanied by HYPERPLASIA of the associated submucosal connective tissue. Polyps may be NEOPLASMS, foci of INFLAMMATION, degenerative lesions, or malformations.	2.11	1
Chronic Illness [description not available]	2.02	1
Asthma, Bronchial [description not available]	2.44	2
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	2.44	2
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	2.02	1
Allergy, Drug [description not available]	2.04	1
Drug Hypersensitivity Immunologically mediated adverse reactions to medicinal substances used legally or illegally.	2.04	1
Palmoplantaris Pustulosis [description not available]	1.98	1
Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.	1.98	1
Adrenoleukodystrophy, Autosomal Neonatal Form [description not available]	1.99	1
Peroxisomal Disorders A heterogeneous group of inherited metabolic disorders marked by absent or dysfunctional PEROXISOMES. Peroxisomal enzymatic abnormalities may be single or multiple. Biosynthetic peroxisomal pathways are compromised, including the ability to synthesize ether lipids and to oxidize long-chain fatty acid precursors. Diseases in this category include ZELLWEGER SYNDROME; INFANTILE REFSUM DISEASE; rhizomelic chondrodysplasia (CHONDRODYSPLASIA PUNCTATA, RHIZOMELIC); hyperpipecolic acidemia; neonatal adrenoleukodystrophy; and ADRENOLEUKODYSTROPHY (X-linked). Neurologic dysfunction is a prominent feature of most peroxisomal disorders.	1.99	1
Cot Death [description not available]	2	1
Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.	2	1

15-hydroxyeicosatrienoic acid

Description

Cross-References

Synonyms (5)

Research

Studies (13)

Market Indicators

Research Demand Index: 11.83

Study Types